PLIANT THERAPEUTICS, INC. Operating Expenses
PLIANT THERAPEUTICS, INC. (PLRX) reported Operating Expenses of $23.86 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $23.86M, a 47.66% decline year-over-year.
- PLIANT THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $21.77M, a 63.06% decline year-over-year.
- PLIANT THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $23.58M, a 55.78% decline year-over-year.
- PLIANT THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $28.27M, a 54.42% decline year-over-year.
- PLIANT THERAPEUTICS, INC. operating expenses for fiscal 2025 was $156.37M, a 31.52% decline from fiscal 2024.
- PLIANT THERAPEUTICS, INC. operating expenses for fiscal 2024 was $228.37M, a 22.96% increase from fiscal 2023.
- PLIANT THERAPEUTICS, INC. operating expenses for fiscal 2023 was $185.72M, a 35.68% increase from fiscal 2022.
- PLIANT THERAPEUTICS, INC. operating expenses for fiscal 2022 was $136.88M, a 30.23% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $23.86M 10-Q · filed 2026-08-11 | $45.63M 10-Q · filed 2026-08-11 | $69.21M derived: sum of 3 quarters · filed 2026-08-11 | $97.48M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $21.77M 10-Q · filed 2026-05-11 | $45.35M derived: sum of 2 quarters · filed 2026-05-11 | $73.62M derived: sum of 3 quarters · filed 2026-05-11 | $119.21M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $23.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $51.85M derived: sum of 2 quarters · filed 2026-03-11 | $97.44M derived: sum of 3 quarters · filed 2026-08-11 | $156.37M 10-K · filed 2026-03-11 |
| 2025-09-30 | $28.27M 10-Q · filed 2025-11-06 | $73.86M derived: sum of 2 quarters · filed 2026-08-11 | $132.80M 10-Q · filed 2025-11-06 | $186.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $45.59M 10-Q · filed 2026-08-11 | $104.53M 10-Q · filed 2026-08-11 | $157.85M derived: sum of 3 quarters · filed 2026-08-11 | $219.86M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $58.94M 10-Q · filed 2026-05-11 | $112.25M derived: sum of 2 quarters · filed 2026-05-11 | $174.27M derived: sum of 3 quarters · filed 2026-05-11 | $234.91M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $53.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $115.33M derived: sum of 2 quarters · filed 2026-03-11 | $175.97M derived: sum of 3 quarters · filed 2026-03-11 | $228.37M 10-K · filed 2026-03-11 |
| 2024-09-30 | $62.01M 10-Q · filed 2025-11-06 | $122.65M derived: sum of 2 quarters · filed 2025-11-06 | $175.04M 10-Q · filed 2025-11-06 | $222.08M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $60.64M 10-Q · filed 2025-08-07 | $113.03M 10-Q · filed 2025-08-07 | $160.07M derived: sum of 3 quarters · filed 2025-08-07 | $207.75M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $52.39M 10-Q · filed 2025-05-08 | $99.43M derived: sum of 2 quarters · filed 2025-05-08 | $147.11M derived: sum of 3 quarters · filed 2025-05-08 | $194.69M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $47.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $94.72M derived: sum of 2 quarters · filed 2025-03-03 | $142.30M derived: sum of 3 quarters · filed 2025-03-03 | $185.72M 10-K · filed 2025-03-03 |
| 2023-09-30 | $47.69M 10-Q · filed 2024-11-07 | $95.26M derived: sum of 2 quarters · filed 2024-11-07 | $138.69M 10-Q · filed 2024-11-07 | $178.05M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $47.58M 10-Q · filed 2024-08-07 | $91.00M 10-Q · filed 2024-08-07 | $130.37M derived: sum of 3 quarters · filed 2025-03-03 | $163.80M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $43.43M 10-Q · filed 2024-05-06 | $82.79M derived: sum of 2 quarters · filed 2025-03-03 | $116.22M derived: sum of 3 quarters · filed 2025-03-03 | $150.85M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $39.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $72.79M derived: sum of 2 quarters · filed 2025-03-03 | $107.42M derived: sum of 3 quarters · filed 2025-03-03 | $136.88M 10-K · filed 2025-03-03 |
| 2022-09-30 | $33.43M 10-Q · filed 2023-11-09 | $68.06M derived: sum of 2 quarters · filed 2023-11-09 | $97.52M 10-Q · filed 2023-11-09 | $124.12M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $34.63M 10-Q · filed 2023-08-09 | $64.09M 10-Q · filed 2023-08-09 | $90.69M derived: sum of 3 quarters · filed 2024-02-27 | $119.41M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $29.46M 10-Q · filed 2023-05-09 | $56.06M derived: sum of 2 quarters · filed 2024-02-27 | $84.78M derived: sum of 3 quarters · filed 2024-02-27 | $109.47M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $26.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $55.32M derived: sum of 2 quarters · filed 2024-02-27 | $80.01M derived: sum of 3 quarters · filed 2024-02-27 | $105.11M 10-K · filed 2024-02-27 |
| 2021-09-30 | $28.72M 10-Q · filed 2022-11-08 | $53.42M derived: sum of 2 quarters · filed 2022-11-08 | $78.51M 10-Q · filed 2022-11-08 | $101.99M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $24.69M 10-Q · filed 2022-08-08 | $49.79M 10-Q · filed 2022-08-08 | $73.27M derived: sum of 3 quarters · filed 2022-08-08 | $94.74M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $25.09M 10-Q · filed 2022-05-09 | $48.57M derived: sum of 2 quarters · filed 2022-05-09 | $70.05M derived: sum of 3 quarters · filed 2022-05-09 | $90.63M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $23.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $44.96M derived: sum of 2 quarters · filed 2022-03-01 | $65.53M derived: sum of 3 quarters · filed 2022-03-01 | $83.46M 10-K · filed 2022-03-01 |
| 2020-09-30 | $21.48M 10-Q · filed 2021-11-09 | $42.05M derived: sum of 2 quarters · filed 2021-11-09 | $59.98M 10-Q · filed 2021-11-09 | $74.81M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $20.58M 10-Q · filed 2021-08-09 | $38.51M 10-Q · filed 2021-08-09 | $53.34M derived: sum of 3 quarters · filed 2022-03-01 | $66.70M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $17.93M 10-Q · filed 2021-05-10 | $32.76M derived: sum of 2 quarters · filed 2022-03-01 | $46.12M derived: sum of 3 quarters · filed 2022-03-01 | $61.86M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $14.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $28.19M derived: sum of 2 quarters · filed 2022-03-01 | $43.93M derived: sum of 3 quarters · filed 2022-03-01 | $58.28M 10-K · filed 2022-03-01 |
| 2019-09-30 | $13.36M 10-Q · filed 2020-11-10 | $29.10M derived: sum of 2 quarters · filed 2020-11-10 | $43.45M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $15.74M 10-Q · filed 2020-08-11 | $30.09M 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |